Amgen and GSK Join TrumpRx, Bringing Listed Drugs to 54

By FieldPulse Staff · March 16, 2026

Tags: strategy, leadership

Amgen and GSK join TrumpRx.gov on March 16, bringing the total to 54 drugs. Amgen lists Amjevita at $299 (80% off list). Analysts question whether listed discounts are meaningful vs. existing rebate structures.

Amgen and GlaxoSmithKline joined the TrumpRx.gov platform on March 16, 2026, expanding the administration's voluntary drug pricing program to 54 drugs from six pharmaceutical companies.

Amgen's Amjevita (adalimumab biosimilar) is listed at $299 — an 80% discount from its $1,484 retail price.

Several GSK respiratory products are also listed at reductions ranging from 30–55% off list price.

The additions follow earlier participation by Eli Lilly, Novo Nordisk, Sanofi, and Johnson & Johnson.

The expansion reflects mounting pressure on large pharma companies to show public goodwill on pricing ahead of potential legislative action on most-favored-nation deals.

However, analysts note that many listed products are already available at lower prices through existing rebate contracts with payers and PBMs, meaning the "discounts" on TrumpRx may be primarily optics against inflated list prices rather than true out-of-pocket reductions for patients.

Source: https://www.statnews.com/2026/03/16/biotech-news-two-more-drugmakers-join-trumprx/